0YC0 Stock Price, Chart, Stats & News

Unity Biotechnology, Inc. is a biotechnology firm dedicated to discovering and advancing therapies designed to slow, halt, or even reverse the progression of diseases associated with aging. The company's primary therapeutic candidate, UBX1325, is currently undergoing Phase II clinical trials, addressing age-related ocular conditions such as diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Its pipeline also features UBX1967, intended for various ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody targeting age-related vision impairments; and UBX2089, an a-Klotho hormone candidate with potential in diverse neurological applications.